Researchers demonstrated that mass drug administration can grant community-level protection against Plasmodium falciparum malaria.
The vaccine can confer up to 100 percent protection and will be tested in 2,100 people on the west African island of Bioko.
Large-scale pig farms in China will now be allowed to test for African swine fever (ASF) in an attempt to detect the virus sooner. This decision overturns an earlier government prohibition on commercial farms carrying out their own testing.
When African swine fever (ASF) hit Poland the authorities, in co-operation with the European Commission, set up three different zones that are each enforced by a different set of regulations, depending on the risk of ASF in that area.
Researchers took advantage of a modified rabies virus vector, and incorporated a gene from Nipah virus - creating a viral particle that displays components of both viruses on its surface.
Of more than 90,000 people who were vaccinated, only 71 went on to develop Ebola. Fifty-six of those people developed symptoms fewer than 10 days after being vaccinated, suggesting the vaccine had not yet had time to fully protect them.
Researchers made two versions of a potential vaccine and evaluated their effectiveness and safety in mice that were genetically altered to have more human-like immune responses. After the mice were vaccinated and then infected with Middle East respiratory syndrome (MERS), both vaccines protected the mice against clinical signs of disease and death.
Biotechnology company Scynexis, Inc., is reporting early but promising results from a phase 3 trial of a novel drug for treating invasive Candida auris infections.
Although vaccines for the plague have been tried for decades, they have given only transient protection, and can’t protect against all forms of the plague, such as pneumonic plague.
The US Biomedical Advanced Research and Development Authority (BARDA) collaborates with JLABS to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases.